You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》瑞銀下調騰盛博藥-B(02137.HK)目標價至26.5元 評級「買入」
瑞銀髮表研究報告指,去年底騰盛博藥(02137.HK)的COVID中和抗體雞尾酒療法獲內地當局批準,消息傳出後公司股價累計下跌約65%,相信主要是由於市場對整個中國醫療保健行業的負面情緒,以及全球新冠療法的潛在競爭所影響。 目前輝瑞(PFE.US)旗下nirmatrelvir等口服COVID藥物已在歐洲、美國及中國等地獲批,因此瑞銀相應下調騰盛博藥COVID 中和抗體的銷售預測,風險調整後峯值銷售預測從25億元人民幣下調至14 億元人民幣,滲透率預測從20%下調至10%。 惟該行表示,仍然看好騰盛博藥在乙型肝炎病毒(HBV)、人類免疫缺陷病毒(HIV)及產後抑鬱症(PPD)領域的綜合產品管線,認爲該公司目前被低估,將2021至2023年每股盈利預測下調至虧損0.73元、盈利0.18元及虧損1.61元人民幣,目標價由47.7元下調至26.5元,維持「買入」評級。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account